In the published article, there was an error in the Funding statement. “This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017202).” The correct Funding statement appears below.
Funding
“This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20001).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
heart failure, myocardial infarction, honokiol, reactive oxygen species, UCP3
Citation
Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H and Chen L (2022) Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition. Front. Pharmacol. 13:1000887. doi: 10.3389/fphar.2022.1000887
Received
22 July 2022
Accepted
17 August 2022
Published
27 September 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Liu, Tang, Li, Su, Zhu, Dou, Liu, Pei, Yang, Ye and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lijuan Chen, chenlijuan125@163.com
†These authors have contributed equally to this work and share first authorship
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.